Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Propanc Biopharma, Inc. (Delaware) on February 21, 2023, covering events occurring on February 14, 2023. The Company, headquartered in Camberwell, Australia, reported the entry into a material definitive agreement and the creation of a direct financial obligation.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard operating financial results. Key metrics include:
- Principal Amount: $111,111 convertible promissory note issued to ONE44 Capital LLC.
- Net Proceeds: $100,000 (after an $11,111 original issue discount).
- Interest Rate: 10% per annum, payable in shares of common stock.
- Maturity Date: February 14, 2024.
- Use of Proceeds: General working capital.
- Conversion Terms: Convertible at 60% of the lowest trading price over the prior 10 trading days (reduces to 50% during a DTC "Chill").
Material Changes and Prepayment Terms
The Company entered into a new debt obligation. The Note includes significant prepayment penalties if repaid within 180 days of issuance:
- 0-60 days: 120% of face amount plus accrued interest.
- 60-120 days: 130% of face amount plus accrued interest.
- 120-180 days: 135% of face amount plus accrued interest.
Upon an event of default, the interest rate accelerates to 24% per annum (or the maximum rate permitted by law).
Outlook, Risks, and Covenants
The filing outlines specific risks and covenants associated with the new debt:
- Asset Disposition Restriction: The Company cannot sell or dispose of substantially all assets outside the ordinary course of business without ONE44's consent, preventing the Company from becoming a "shell company."
- Conversion Cap: ONE44 is restricted from converting if it would exceed 4.99% of outstanding shares (increasable to 9.9% with notice).
- Default Risks: Includes failure to issue shares timely, insolvency, bankruptcy, or breach of covenants.
- Regulatory Status: Securities were issued in a private placement under Section 4(a)(2) of the Securities Act and/or Regulation D.
The filing text does not provide updated revenue, profit, cash flow, or liquidity metrics beyond the proceeds from this specific transaction.
Investor Verification Checklist
- Verify the current trading price of Propanc Biopharma common stock to assess the potential dilution impact of the 60% conversion discount.
- Confirm the Company's current cash position to evaluate its ability to meet the $111,111 principal obligation at maturity in February 2024.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.41) for additional covenants not summarized in the 8-K.
- Monitor for any DTC "Chill" status on the Company's shares, which would lower the conversion price to 50%.
- Check subsequent filings for any acceleration of the note or default events.